Pharmacy Closures and Medication Adherence: What’s the Link?
Pharmacy closures appear to impact cardiovascular medication adherence among older patients, according to findings from a retrospective cohort study published in JAMA Network Open.
CHF and Arrhythmias
Evidence Supporting Niacin Use for Cardiovascular Disease Prevention Evaluated
According to the results of a systematic review and meta-analysis, evidence supporting the clinical benefit of niacin monotherapy for secondary prevention of cardiovascular disease (CVD) appears to be outdated and may require further prospective trials to determine its role in CVD management.
New-Onset Non-Ischemic Cardiomyopathy Linked to Gabapentin Use
A recently published report describes the case of a patient who developed non-ischemic cardiomyopathy following initiation of gabapentin therapy for pain management.
More Secondary Prevention Meds May Reduce Deaths After AMI
Mortality lower with more meds for older nursing home residents after acute myocardial infarction
Yosprala Available Again for Secondary Prevention of CVD With Gastroprotection
Genus Lifesciences has announced the re-introduction of Yosprala delayed-release tablets to the US market.
Ready-to-Administer Adenosine Simplist Syringes Now Available
Fresenius Kabi announced the launch of Adenosine Injection, USP, 6mg/2mL and 12mg/4mL, in single-dose Simplist ready-to-administer prefilled syringes.
New FDA-Approved Treatment Significantly Reduces Infarct Size in MI Patients
TherOx has received premarket approval from the Food and Drug Administration (FDA) for SuperSaturated Oxygen (SSO2) Therapy for use in patients who suffer left anterior descending (LAD) ST-elevation myocardial infarction.
Tudorza Pressair Labeling Updated With Data Related to COPD Patients With Cardiovascular Comorbidity
The Food and Drug Administration (FDA) has approved the inclusion of new data from the ASCENT trial in the prescribing information for Tudorza Pressair (aclidinium bromide inhalation powder; Circassia), an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). In ASCENT, the effect of Tudorza on major adverse cardiovascular events…
Real-World Study Data Comparing Empagliflozin vs DPP-4 Inhibitors
Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego.
First-in-Class Device Approved to Treat Moderate to Severe Chronic Heart Failure
The Food and Drug Administration (FDA) has approved the Optimizer Smart System (Impulse Dynamics) for use in patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac resynchronization therapy.
